There are currently approximately 16 million people taking NNRTI-based first-line treatment
in low-income and middle-income countries. Most of these patients are using the …

Neuropsychiatric adverse events (NPAEs) observed with the integrase strand transfer
inhibitor (INSTI) dolutegravir (DTG) are usually mild to moderate. The most prevalent …

Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …

Background A preliminary safety signal for neural-tube defects was previously reported in
association with dolutegravir exposure from the time of conception, which has affected …

Background Effective two-drug regimens could decrease long-term drug exposure and
toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy …

Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …

Key updates ÿ A recommendation for dolutegravir (DTG)-based therapies as the preferred
first-line antiretroviral therapy (ART) option (section 11). ÿ Updated guidelines for second …

To increase the success in Covid 19 treatment, many drug suggestions are presented, and
some clinical studies are shared in the literature. There have been some attempts to use …

Background Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to
dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not …

Integrase strand transfer inhibitors (INSTIs) are currently recommended for the first line
treatment of human immunodeficiency virus type one (HIV-1) infection. The first-generation …